Statins and Cholesterol: It’s How You Lower It
Your cholesterol went up. Did anyone ask why?
A few weeks ago I watched a cardiologist in her mid-thirties tell her followers she had started a statin. The statin, she said, was for her future self.
No trial has ever tested whether a statin prevents a single heart attack or death in healthy adults under 40 who don't have a genetic cholesterol disorder. The people in the big statin trials averaged 63 years old, and the trials ran about four years. And nobody in that story asked the question this whole episode is built on: why did the number go up in the first place?
Cholesterol is raw material
Most people picture cholesterol as gunk in a pipe, when your body treats it as raw material. Every cell wall is built with it, and every steroid hormone you make starts from it: progesterone, DHEA, testosterone, estradiol and cortisol.
Lower isn't automatically better, either. In about 70 of roughly 95 cohort studies, people whose cholesterol ran naturally low died at higher rates than people in the middle. Illness pulls cholesterol down too, so part of that runs the other way, but your body still doesn't treat cholesterol as trash.
Why the number climbs in midlife
In women, LDL climbs on the same schedule hormones fall. When researchers lined women's cholesterol up against their own final period, LDL rose more than three times faster in the couple of years around it than before it, independent of age, and after it the climb nearly stopped. Estradiol helps your liver keep the receptors that pull LDL out of the blood. When estradiol leaves, clearance slows.
Thyroid is the strongest lever in this whole body of research. When people whose thyroid has been removed come off their thyroid hormone for a few weeks, their LDL runs about 70 points higher than once they're back on it. In 2015 an international lipid panel, 13 of its 31 members tied to the companies that make cholesterol drugs, wrote that thyroid should be checked before any statin starts.
In men, lower testosterone travels with the metabolic syndrome, and underneath all of it sits insulin resistance. Anything that improves insulin sensitivity is a cholesterol treatment, whether or not anybody calls it one.
What a statin actually does
A statin blocks one step early in the liver's factory line, and that step feeds much more than cholesterol. It also supplies coenzyme Q10, which your mitochondria use to make energy, and below cholesterol sit your steroid hormones. Picture a dam near the source of a river. The cholesterol town runs dry, which is the point, and some of the other towns get less water too: CoQ10 falls, and so does testosterone.
In a 2013 trial, sedentary adults carrying extra weight trained for 12 weeks. Without a statin their fitness rose about 10%, and with one, about 1.5%. The energy-making machinery in their muscles grew about 13% without the drug and didn't grow with it.
A statin lowers the number without touching why it rose. It also changes your calcium score: in the words of a 2015 analysis of the plaque-imaging trials, statins promote calcium in the plaque. So a score taken on a statin can't be read the same way as one taken before it.
The real numbers
"38% fewer heart attacks" sounds enormous. In people without heart disease, it comes to about 7 fewer heart attacks for every 1,000 people taking a statin for four to five years. Of ten pooled estimates, six found no significant difference in deaths from any cause, though all ten leaned toward fewer, and within the trials the extra life averaged out to about six to ten days.
After a heart attack, or with established heart and artery disease, the numbers change. That is where statins are at their strongest: about two fewer heart attacks per 100 people over four to five years, and deaths from any cause about 17% lower, about two fewer per 100 over five years. If that's you, those numbers belong in a conversation with your cardiologist, and your hormones, thyroid and insulin still matter alongside them.
The price
The biggest cost is blood sugar. On a high-dose statin, about 1 extra person in 80 is diagnosed with diabetes each year, and about six in ten of those extra cases land in people whose blood sugar was already in the top quarter. The people closest to the line get pushed over it, and that is often the insulin-resistant patient whose cholesterol rose in the first place.
Statins also lower testosterone in men, more at higher doses. In men who were already low, switching to a high-dose statin took another 15 to 19% off in four months. For a man just above the line the FDA uses to call it low, that's enough to put him under it, for as long as he takes the drug. Serious muscle damage is rare and tied to dose and genes. Milder muscle pain is real for some people, and only one of 42 statin trials specifically asked about it.
Hormones push the other way. Across randomized trials in women past menopause, new diabetes ran about 30% lower on hormone therapy.
How you lower it
It can be the same lower number on the panel with a very different body underneath. Oral estradiol lowers LDL, lowers ApoB and lowers Lp(a), which very little else moves. Taken alone or with progesterone, it raises HDL. Triglycerides tick up modestly at first, and in my experience that settles. The patch lowers LDL more gently, and it's a good option and her choice. For men, I add oral estradiol on top of testosterone, because estradiol is what moves ApoB down and ApoA up. And when thyroid is truly low, treating it is the biggest single cholesterol move in the research.
The numbers I watch hardest aren't LDL. My targets are an ApoB under 90, an ApoA-1 over 125, an HDL over 60 and triglycerides under 50, optimal, not just normal. In women I want estradiol at least 75, a floor, not a ceiling.
Questions for your next appointment
What is my absolute risk, out of 100 people like me over five years, and how much does this drug change it? Is this to prevent a first heart attack or a second one? Have my thyroid and my hormones been checked? What does my calcium score show, and was it taken before the statin?
Then you decide, with the person who prescribes it. Nobody should stop a prescribed medicine because of an article; this is a reason to walk in with better questions than the prescriber expected. And if your doctor gets upset by these questions, it's time to find a new doctor.
The whole argument:
Listen to podcast Part One on Spotify
⚠️ Educational content, not individual medical advice or a treatment recommendation. Nobody should start, stop or change a prescription because of an article. Your labs and history belong in a one on one.
🩺 DNP led telehealth hormone optimization. Book a consultation and find everything: withinyou.health/links
Sources
Abramson, J. D., Rosenberg, H. G., Jewell, N., & Wright, J. M. (2013). Should people at low risk of cardiovascular disease take a statin? BMJ, 347, f6123. https://doi.org/10.1136/bmj.f6123
Ades, P. A. (2014). A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Coron Artery Dis, 25(4), 360-3. https://doi.org/10.1097/MCA.0000000000000086
Albayda, J., & Christopher-Stine, L. (2014). Identifying statin-associated autoimmune necrotizing myopathy. Cleve Clin J Med, 81(12), 736-41. https://doi.org/10.3949/ccjm.81a.13158
Ambikairajah, A., Walsh, E., & Cherbuin, N. (2019). Lipid profile differences during menopause: a review with meta-analysis. Menopause, 26(11), 1327-1333. https://doi.org/10.1097/GME.0000000000001403
Anagnostis, P., Galanis, P., Chatzistergiou, V., Stevenson, J. C., Godsland, I. F., Lambrinoudaki, I., Theodorou, M., & Goulis, D. G. (2017). The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. Maturitas, 99, 27-36. https://doi.org/10.1016/j.maturitas.2017.02.009
Antonio, L., Wu, F. C., O'Neill, T. W., Pye, S. R., Carter, E. L., Finn, J. D., Rutter, M. K., Laurent, M. R., Huhtaniemi, I. T., Han, T. S., Lean, M. E., Keevil, B. G., Pendleton, N., Rastrelli, G., Forti, G., Bartfai, G., Casanueva, F. F., Kula, K., Punab, M., . . . Vanderschueren, D. (2015). Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. J Clin Endocrinol Metab, 100(4), 1396-404. https://doi.org/10.1210/jc.2014-4184
Arad, Y., Spadaro, L. A., Roth, M., Newstein, D., & Guerci, A. D. (2005). Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol, 46(1), 166-72. https://doi.org/10.1016/j.jacc.2005.02.089
Ball, M. J., Griffiths, D., & Thorogood, M. (1991). Asymptomatic hypothyroidism and hypercholesterolaemia. J R Soc Med, 84(9), 527-9. https://doi.org/10.1177/014107689108400908
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., Greenfield, R. S., Hovingh, G. K., Kostner, K., Serban, C., Lighezan, D., Fras, Z., Moriarty, P. M., Muntner, P., Goudev, A., . . . Mikhailidis, D. P. (2015). Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci, 11(1), 1-23. https://doi.org/10.5114/aoms.2015.49807
Banach, M., Serban, C., Sahebkar, A., Ursoniu, S., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Glasser, S. P., Lip, G. Y., Dragan, S., & Mikhailidis, D. P. (2015). Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc, 90(1), 24-34. https://doi.org/10.1016/j.mayocp.2014.08.021
Banach, M., Serban, C., Ursoniu, S., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Glasser, S. P., Watts, G. F., Blumenthal, R. S., Lip, G. Y., Mikhailidis, D. P., & Sahebkar, A. (2015). Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res, 99, 329-36. https://doi.org/10.1016/j.phrs.2015.07.008
Banaszewska, B., Pawelczyk, L., Spaczynski, R. Z., & Duleba, A. J. (2011). Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab, 96(11), 3493-501. https://doi.org/10.1210/jc.2011-0501
Bardoczi, J. B., Brunner, L., Spinewine, A., Rodondi, N., & Aubert, C. E. (2024). Older Adult Attitudes toward Deprescribing Statins in Primary Cardiovascular Prevention Versus General Medications. Gerontol Geriatr Med, 10, 23337214241245918. https://doi.org/10.1177/23337214241245918
Bassler, D., Briel, M., Montori, V. M., Lane, M., Glasziou, P., Zhou, Q., Heels-Ansdell, D., Walter, S. D., Guyatt, G. H., Flynn, D. N., Elamin, M. B., Murad, M. H., Abu Elnour, N. O., Lampropulos, J. F., Sood, A., Mullan, R. J., Erwin, P. J., Bankhead, C. R., Perera, R., . . . Ramsay, T. (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA, 303(12), 1180-7. https://doi.org/10.1001/jama.2010.310
Bérczi, B., Farkas, N., Hegyi, P., Tóth, B., Csupor, D., Németh, B., Lukács, A., Czumbel, L. M., Kerémi, B., Kiss, I., Szabó, A., Varga, G., Gerber, G., & Gyöngyi, Z. (2024). Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis. J Clin Med, 13(6), doi: 10.3390/jcm13061818. https://doi.org/10.3390/jcm13061818
Bero, L., Oostvogel, F., Bacchetti, P., & Lee, K. (2007). Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med, 4(6), e184. https://doi.org/10.1371/journal.pmed.0040184
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roqué i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015). Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev, 2015(3), CD002229. https://doi.org/10.1002/14651858.CD002229.pub4
Bretler, D. M., Hansen, P. R., Sørensen, R., Lindhardsen, J., Ahlehoff, O., Andersson, C., Abildstrøm, S. Z., Torp-Pedersen, C., & Gislason, G. H. (2012). Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study. BMJ, 344, e1802. https://doi.org/10.1136/bmj.e1802
Bukkapatnam, R. N., Gabler, N. B., & Lewis, W. R. (2010). Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol, 13(2), 84-90. https://doi.org/10.1111/j.1751-7141.2009.00059.x
Byrne, P., Cullinan, J., Smith, A., & Smith, S. M. (2019). Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open, 9(4), e023085. https://doi.org/10.1136/bmjopen-2018-023085
Byrne, P., Demasi, M., Jones, M., Smith, S. M., O'Brien, K. K., & DuBroff, R. (2022). Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. JAMA Intern Med, 182(5), 474-481. https://doi.org/10.1001/jamainternmed.2022.0134
Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., Reiner Ž, Toth, P. P., & Banach, M. (2022). Prevalence of statin intolerance: a meta-analysis. Eur Heart J, 43(34), 3213-3223. https://doi.org/10.1093/eurheartj/ehac015
Cai, T., Abel, L., Langford, O., Monaghan, G., Aronson, J. K., Stevens, R. J., Lay-Flurrie, S., Koshiaris, C., McManus, R. J., Hobbs, F. D. R., & Sheppard, J. P. (2021). Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ, 374, n1537. https://doi.org/10.1136/bmj.n1537
Carling, C. L., Kristoffersen, D. T., Montori, V. M., Herrin, J., Schünemann, H. J., Treweek, S., Akl, E. A., & Oxman, A. D. (2009). The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial. PLoS Med, 6(8), e1000134. https://doi.org/10.1371/journal.pmed.1000134
Catalá-López, F., Sanfélix-Gimeno, G., Ridao, M., & Peiró, S. (2013). When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins. PLoS One, 8(7), e69462. https://doi.org/10.1371/journal.pone.0069462
Celi, F. S., Zemskova, M., Linderman, J. D., Smith, S., Drinkard, B., Sachdev, V., Skarulis, M. C., Kozlosky, M., Csako, G., Costello, R., & Pucino, F. (2011). Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab, 96(11), 3466-74. https://doi.org/10.1210/jc.2011-1329
Cherry, N., McNamee, R., Heagerty, A., Kitchener, H., & Hannaford, P. (2014). Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG, 121(6), 700-5; discussion 705. https://doi.org/10.1111/1471-0528.12598
Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., Sullivan, L., Vasan, R. S., Wilson, P. W., & D'Agostino, R. B. (2007). LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol, 1(6), 583-92. https://doi.org/10.1016/j.jacl.2007.10.001
CTT Collaboration. (2019). Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, 393(10170), 407-415. https://doi.org/10.1016/S0140-6736(18)31942-1
CTT Collaboration. (2022). Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet, 400(10355), 832-845. https://doi.org/10.1016/S0140-6736(22)01545-8
CTT Collaboration. (2024). Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol, 12(5), 306-319. https://doi.org/10.1016/S2213-8587(24)00040-8
CTT Collaboration. (2026). Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet, 407(10529), 689-703. https://doi.org/10.1016/S0140-6736(25)01578-8
de Keyser, C. E., de Lima, F. V., de Jong, F. H., Hofman, A., de Rijke, Y. B., Uitterlinden, A. G., Visser, L. E., & Stricker, B. H. (2015). Use of statins is associated with lower serum total and non-sex hormone-binding globulin-bound testosterone levels in male participants of the Rotterdam Study. Eur J Endocrinol, 173(2), 155-65. https://doi.org/10.1530/EJE-14-1061
de Lauzon-Guillain, B., Fournier, A., Fabre, A., Simon, N., Mesrine, S., Boutron-Ruault, M. C., Balkau, B., & Clavel-Chapelon, F. (2009). Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort. Diabetologia, 52(10), 2092-100. https://doi.org/10.1007/s00125-009-1456-y
de Lorgeril, M., Salen, P., Abramson, J., Dodin, S., Hamazaki, T., Kostucki, W., Okuyama, H., Pavy, B., & Rabaeus, M. (2010). Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med, 170(12), 1032-6. https://doi.org/10.1001/archinternmed.2010.184
Demasi, M. (2018). Statin wars: have we been misled about the evidence? A narrative review. Br J Sports Med, 52(14), 905-909. https://doi.org/10.1136/bjsports-2017-098497
Derby, C. A., Crawford, S. L., Pasternak, R. C., Sowers, M., Sternfeld, B., & Matthews, K. A. (2009). Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol, 169(11), 1352-61. https://doi.org/10.1093/aje/kwp043
Dobs, A. S., Schrott, H., Davidson, M. H., Bays, H., Stein, E. A., Kush, D., Wu, M., Mitchel, Y., & Illingworth, R. D. (2000). Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism, 49(9), 1234-8. https://doi.org/10.1053/meta.2000.7716a
Doshi, P., Hong, K., Tanveer, S., & Jefferson, T. (2022). Assessing Muscle-Related Adverse Events in Randomized Trials of Statins. J Gen Intern Med, 37(13), 3498-3500. https://doi.org/10.1007/s11606-022-07485-6
El Khoudary, S. R., Chen, X., Wang, Z., Brooks, M. M., Orchard, T., Crawford, S., Janssen, I., Everson-Rose, S. A., McConnell, D., & Matthews, K. (2023). Low-density lipoprotein subclasses over the menopausal transition and risk of coronary calcification and carotid atherosclerosis: the SWAN Heart and HDL ancillary studies. Menopause, 30(10), 1006-1013. https://doi.org/10.1097/GME.0000000000002245
Elraiyah, T., Sonbol, M. B., Wang, Z., Khairalseed, T., Asi, N., Undavalli, C., Nabhan, M., Altayar, O., Prokop, L., Montori, V. M., & Murad, M. H. (2014). Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab, 99(10), 3536-42. https://doi.org/10.1210/jc.2014-2261
Espeland, M. A., Marcovina, S. M., Miller, V., Wood, P. D., Wasilauskas, C., Sherwin, R., Schrott, H., & Bush, T. L. (1998). Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation, 97(10), 979-86. https://doi.org/10.1161/01.cir.97.10.979
ESPRIT Team. (2002). Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet, 360(9350), 2001-8. https://doi.org/10.1016/s0140-6736(02)12001-0
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014). A systematic review of statin-induced muscle problems in clinical trials. Am Heart J, 168(1), 6-15. https://doi.org/10.1016/j.ahj.2014.03.019
Garcia, C., Dusaud, M., Chiron, P., Sollier, M., Nassouri, S., Groussin, L., Sibony, M., Goursaud, C., Roucher-Boulez, F., & Bordier, L. (2021). Atypical Presentation of Testicular Adrenal Rest Tumor (TART) Leading to Bilateral Partial Orchiectomy in a 31-Year-Old Adult Revealing Primary Adrenal Insufficiency with CYP11A1 Deficiency. Case Rep Endocrinol, 2021, 5889007. https://doi.org/10.1155/2021/5889007
Ghosh, M., Gälman, C., Rudling, M., & Angelin, B. (2015). Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. J Lipid Res, 56(2), 463-9. https://doi.org/10.1194/jlr.M055780
Goldstein, L. B., Amarenco, P., Szarek, M., Callahan A 3rd, Hennerici, M., Sillesen, H., Zivin, J. A., & Welch, K. M. (2008). Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology, 70(24 Pt 2), 2364-70. https://doi.org/10.1212/01.wnl.0000296277.63350.77
Gordon, J. L., Rubinow, D. R., Watkins, L., Hinderliter, A. L., Caughey, M. C., & Girdler, S. S. (2020). The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease. J Clin Endocrinol Metab, 105(5), e2050-60. https://doi.org/10.1210/clinem/dgz262
Hansen, M. R., Hróbjartsson, A., Pottegård, A., Damkier, P., Larsen, K. S., Madsen, K. G., dePont Christensen, R., Kristensen, M. E. L., Christensen, P. M., & Hallas, J. (2019). Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials. J Gen Intern Med, 34(8), 1607-1614. https://doi.org/10.1007/s11606-019-05024-4
Harman, S. M., Brinton, E. A., Cedars, M., Lobo, R., Manson, J. E., Merriam, G. R., Miller, V. M., Naftolin, F., & Santoro, N. (2005). KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric, 8(1), 3-12. https://doi.org/10.1080/13697130500042417
Hodis, H. N., Mack, W. J., Lobo, R. A., Shoupe, D., Sevanian, A., Mahrer, P. R., Selzer, R. H., Liu Cr, C. R., Liu Ch, C. H., & Azen, S. P. (2001). Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 135(11), 939-53. https://doi.org/10.7326/0003-4819-135-11-200112040-00005
Hodis, H. N., Mack, W. J., Azen, S. P., Lobo, R. A., Shoupe, D., Mahrer, P. R., Faxon, D. P., Cashin-Hemphill, L., Sanmarco, M. E., French, W. J., Shook, T. L., Gaarder, T. D., Mehra, A. O., Rabbani, R., Sevanian, A., Shil, A. B., Torres, M., Vogelbach, K. H., & Selzer, R. H. (2003). Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med, 349(6), 535-45. https://doi.org/10.1056/NEJMoa030830
Hodis, H. N., & Mack, W. J. (2015). Hormone therapy and risk of all-cause mortality in women treated with statins. Menopause, 22(4), 363-4. https://doi.org/10.1097/GME.0000000000000458
Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., Li, Y., Feng, M., Dustin, L., Kono, N., Stanczyk, F. Z., Selzer, R. H., & Azen, S. P. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med, 374(13), 1221-31. https://doi.org/10.1056/NEJMoa1505241
Hooper, L., Martin, N., Jimoh, O. F., Kirk, C., Foster, E., & Abdelhamid, A. S. (2020). Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev, 8(8), CD011737. https://doi.org/10.1002/14651858.CD011737.pub3
Houslay, E. S., Cowell, S. J., Prescott, R. J., Reid, J., Burton, J., Northridge, D. B., Boon, N. A., & Newby, D. E. (2006). Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart, 92(9), 1207-12. https://doi.org/10.1136/hrt.2005.080929
Hsia, J., Otvos, J. D., Rossouw, J. E., Wu, L., Wassertheil-Smoller, S., Hendrix, S. L., Robinson, J. G., Lund, B., & Kuller, L. H. (2008). Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. Arterioscler Thromb Vasc Biol, 28(9), 1666-71. https://doi.org/10.1161/ATVBAHA.108.170431
Hyyppä, M. T., Kronholm, E., Virtanen, A., Leino, A., & Jula, A. (2003). Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology, 28(2), 181-194. https://doi.org/10.1016/s0306-4530(02)00014-8
Isidori, A. M., Giannetta, E., Greco, E. A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A., & Fabbri, A. (2005). Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf), 63(3), 280-93. https://doi.org/10.1111/j.1365-2265.2005.02339.x
Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019). Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol, 7(10), 754-766. https://doi.org/10.1016/S2213-8587(19)30189-5
Iso, H., Jacobs DR Jr, Wentworth, D., Neaton, J. D., & Cohen, J. D. (1989). Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med, 320(14), 904-10. https://doi.org/10.1056/NEJM198904063201405
Jonklaas, J. (2024). Hypothyroidism, lipids, and lipidomics. Endocrine, 84(2), 293-300. https://doi.org/10.1007/s12020-023-03420-9
Kahoul, R., Gueyffier, F., Amsallem, E., Haugh, M., Marchant, I., Boissel, F. H., & Boissel, J. P. (2014). Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population. J R Soc Interface, 11(100), 20140867. https://doi.org/10.1098/rsif.2014.0867
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E. (2003). Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 138(1), 1-9. https://doi.org/10.7326/0003-4819-138-1-200301070-00005
Kastelein, J. J., Akdim, F., Stroes, E. S., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F., Visseren, F. L., Sijbrands, E. J., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med, 358(14), 1431-43. https://doi.org/10.1056/NEJMoa0800742
Kearns, C. E., Schmidt, L. A., & Glantz, S. A. (2016). Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents. JAMA Intern Med, 176(11), 1680-1685. https://doi.org/10.1001/jamainternmed.2016.5394
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol, 24(27), 4448-56. https://doi.org/10.1200/JCO.2006.06.2497
Keleşoğlu, M., Kızılay, F., Barutçuoğlu, B., Başol, G., Saraç, F., Mutaf, I., & Semerci, B. (2018). The relationship between lipoprotein-associated phospholipase A2 with cardiovascular risk factors in testosterone deficiency. Turk J Urol, 44(2), 103-108. https://doi.org/10.5152/tud.2017.30633
Kotwal, A., Cortes, T., Genere, N., Hamidi, O., Jasim, S., Newman, C. B., Prokop, L. J., Murad, M. H., & Alahdab, F. (2020). Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab, 105(12), pii: dgaa672. doi: 10.1210/clinem/dgaa672. https://doi.org/10.1210/clinem/dgaa672
Kristensen, M. L., Christensen, P. M., & Hallas, J. (2015). The effect of statins on average survival in randomised trials, an analysis of end point postponement. BMJ Open, 5(9), e007118. https://doi.org/10.1136/bmjopen-2014-007118
Krysiak, R., Basiak, M., Szkróbka, W., & Okopień, B. (2021). The impact of rosuvastatin on hypothalamic-pituitary-testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study. Pharmacol Rep, 73(5), 1465-1472. https://doi.org/10.1007/s43440-021-00289-1
Krysiak, R., Kowalcze, K., & Okopień, B. (2021). The impact of hypotestosteronemia on cardiometabolic effects of atorvastatin in men with hypercholesterolemia: a pilot study. Coron Artery Dis, 32(8), 706-712. https://doi.org/10.1097/MCA.0000000000001031
Kuhl, H. (2005). Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric, 8 Suppl 1, 3-63. https://doi.org/10.1080/13697130500148875
Langley, R. E., Cafferty, F. H., Alhasso, A. A., Rosen, S. D., Sundaram, S. K., Freeman, S. C., Pollock, P., Jinks, R. C., Godsland, I. F., Kockelbergh, R., Clarke, N. W., Kynaston, H. G., Parmar, M. K., & Abel, P. D. (2013). Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol, 14(4), 306-16. https://doi.org/10.1016/S1470-2045(13)70025-1
Lasco, A., Frisina, N., Morabito, N., Gaudio, A., Morini, E., Trifiletti, A., Basile, G., Nicita-Mauro, V., & Cucinotta, D. (2001). Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol, 145(4), 457-61. https://doi.org/10.1530/eje.0.1450457
Lauritzen, T., Munkhaugen, J., Bergan, S., Sverre, E., Peersen, K., Lindahl, S., Husebye, E., & Vethe, N. T. (2024). Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease. Clin Transl Sci, 17(10), e70025. https://doi.org/10.1111/cts.70025
Lee, Y. B., Koo, M., Noh, E., Hwang, S. Y., Kim, J. A., Roh, E., Hong, S. H., Choi, K. M., Baik, S. H., Cho, G. J., & Yoo, H. J. (2022). Myocardial Infarction, Stroke, and All-Cause Mortality according to Low-Density Lipoprotein Cholesterol Level in the Elderly, a Nationwide Study. Diabetes Metab J, 46(5), 722-732. https://doi.org/10.4093/dmj.2021.0225
Li, M., Wang, X., Li, X., Chen, H., Hu, Y., Zhang, X., Tang, X., Miao, Y., Tian, G., & Shang, H. (2019). Statins for the primary prevention of coronary heart disease. Biomed Res Int, 2019, 4870350. https://doi.org/10.1155/2019/4870350
Liaigre, L., Guigui, A., Manceau, M., Cracowski, J. L., Khouri, C., & Roustit, M. (2025). Trial-level surrogacy of non-high-density and low-density lipoprotein cholesterol reduction on the clinical efficacy of statins. Eur Heart J Cardiovasc Pharmacother, 11(4), 387-392. https://doi.org/10.1093/ehjcvp/pvaf016
Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson IM Jr, Wang, Q., Wolski, K., Davey, D., Kalahasti, V., Khan, N., Miller, M. G., Snabes, M. C., Chan, A., Dubcenco, E., . . . Nissen, S. E. (2023). Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med, 389(2), 107-117. https://doi.org/10.1056/NEJMoa2215025
Liu, G., Shi, M., Mosley, J. D., Weng, C., Zhang, Y., Lee, M. T. M., Jarvik, G. P., Hakonarson, H., Namjou-Khales, B., Sleiman, P., Luo, Y., Mentch, F., Denny, J. C., Linton, M. F., Wei, W. Q., Stein, C. M., & Feng, Q. (2021). A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes. JAMA Netw Open, 4(6), e2112820. https://doi.org/10.1001/jamanetworkopen.2021.12820
London, E., Tatsi, C., Soldin, S. J., Wassif, C. A., Backlund, P., Ng, D., Biesecker, L. G., & Stratakis, C. A. (2020). Acute Statin Administration Reduces Levels of Steroid Hormone Precursors. Horm Metab Res, 52(10), 742-746. https://doi.org/10.1055/a-1099-9556
Mangone, L. A., Taylor, B. A., Schmelzer, R., Noh, S. G., White, M. C., Kwon, O. S., & Thompson, P. D. (2024). Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS). Open Heart, 11(1), doi: 10.1136/openhrt-2023-002551. https://doi.org/10.1136/openhrt-2023-002551
Matthews, K. A., Crawford, S. L., Chae, C. U., Everson-Rose, S. A., Sowers, M. F., Sternfeld, B., & Sutton-Tyrrell, K. (2009). Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol, 54(25), 2366-2373. https://doi.org/10.1016/j.jacc.2009.10.009
Mazidi, M., Rezaie, P., Vatanparast, H., & Kengne, A. P. (2017). Effect of statins on serum vitamin D concentrations: a systematic review and meta-analysis. Eur J Clin Invest, 47(1), 93-101. https://doi.org/10.1111/eci.12698
Mikus, C. R., Boyle, L. J., Borengasser, S. J., Oberlin, D. J., Naples, S. P., Fletcher, J., Meers, G. M., Ruebel, M., Laughlin, M. H., Dellsperger, K. C., Fadel, P. J., & Thyfault, J. P. (2013). Simvastatin impairs exercise training adaptations. J Am Coll Cardiol, 62(8), 709-14. https://doi.org/10.1016/j.jacc.2013.02.074
Mitchell, J. D., Fergestrom, N., Gage, B. F., Paisley, R., Moon, P., Novak, E., Cheezum, M., Shaw, L. J., & Villines, T. C. (2018). Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. J Am Coll Cardiol, 72(25), 3233-3242. https://doi.org/10.1016/j.jacc.2018.09.051
Mortensen, M. B., Falk, E., Li, D., Nasir, K., Blaha, M. J., Sandfort, V., Rodriguez, C. J., Ouyang, P., & Budoff, M. (2018). Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. JACC Cardiovasc Imaging, 11(2 Pt 1), 221-230. https://doi.org/10.1016/j.jcmg.2017.01.029
Mortensen, M. B., & Nordestgaard, B. G. (2019). Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. JAMA Cardiol, 4(11), 1131-1138. https://doi.org/10.1001/jamacardio.2019.3665
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990). Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ, 301(6747), 309-14. https://doi.org/10.1136/bmj.301.6747.309
Muldoon, M. F., Barger, S. D., Ryan, C. M., Flory, J. D., Lehoczky, J. P., Matthews, K. A., & Manuck, S. B. (2000). Effects of lovastatin on cognitive function and psychological well-being. Am J Med, 108(7), 538-46. https://doi.org/10.1016/s0002-9343(00)00353-3
Nasr, A., Matthews, K. A., Brooks, M. M., McConnell, D. S., Orchard, T. J., Billheimer, J., Rader, D. J., & El Khoudary, S. R. (2020). Vasomotor symptoms and lipids/lipoprotein subclass metrics in midlife women: Does level of endogenous estradiol matter? The SWAN HDL Ancillary Study. J Clin Lipidol, 14(5), 685-694.e2. https://doi.org/10.1016/j.jacl.2020.07.002
Nudy, M., Chinchilli, V. M., & Foy, A. J. (2019). A systematic review and meta-regression analysis to examine the 'timing hypothesis' of hormone replacement therapy on mortality, coronary heart disease, and stroke. Int J Cardiol Heart Vasc, 22, 123-131. https://doi.org/10.1016/j.ijcha.2019.01.001
Paassilta, M., Karjalainen, A., Kervinen, K., Savolainen, M. J., Heikkinen, J., Bäckström, A. C., & Kesäniemi, Y. A. (2000). Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis, 149(1), 157-62. https://doi.org/10.1016/s0021-9150(99)00318-4
Pacanowski, M. A., Frye, R. F., Enogieru, O., Schofield, R. S., & Zineh, I. (2008). Plasma Coenzyme Q10 Predicts Lipid-lowering Response to High-Dose Atorvastatin. J Clin Lipidol, 2(4), 289-97. https://doi.org/10.1016/j.jacl.2008.05.001
Park, J., Son, M. K., & Park, H. Y. (2023). Substantial Lipid Increases During Menopausal Transition in Korean Middle-Aged Women. J Korean Med Sci, 38(31), e238. https://doi.org/10.3346/jkms.2023.38.e238
Pearce, E. N., Wilson, P. W., Yang, Q., Vasan, R. S., & Braverman, L. E. (2008). Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort. J Clin Endocrinol Metab, 93(3), 888-94. https://doi.org/10.1210/jc.2007-1987
PEPI Writing Group. (1995). Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA, 273(3), 199-208.
Puri, R., Nicholls, S. J., Shao, M., Kataoka, Y., Uno, K., Kapadia, S. R., Tuzcu, E. M., & Nissen, S. E. (2015). Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol, 65(13), 1273-1282. https://doi.org/10.1016/j.jacc.2015.01.036
Raittinen, P. V. H., Syvälä, H., Tammela, T. L. J., Häkkinen, M. R., Ilmonen, P., Auriola, S., & Murtola, T. J. (2021). Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. EBioMedicine, 68, 103432. https://doi.org/10.1016/j.ebiom.2021.103432
Raja-Khan, N., Kunselman, A. R., Hogeman, C. S., Stetter, C. M., Demers, L. M., & Legro, R. S. (2011). Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertil Steril, 95(5), 1849-52. https://doi.org/10.1016/j.fertnstert.2010.11.040
Ramos, R., Comas-Cufí, M., Martí-Lluch, R., Balló, E., Ponjoan, A., Alves-Cabratosa, L., Blanch, J., Marrugat, J., Elosua, R., Grau, M., Elosua-Bayes, M., García-Ortiz, L., & Garcia-Gil, M. (2018). Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ, 362, k3359. https://doi.org/10.1136/bmj.k3359
Ramsden, C. E., Zamora, D., Leelarthaepin, B., Majchrzak-Hong, S. F., Faurot, K. R., Suchindran, C. M., Ringel, A., Davis, J. M., & Hibbeln, J. R. (2013). Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ, 346, e8707. https://doi.org/10.1136/bmj.e8707
Ramsden, C. E., Zamora, D., Majchrzak-Hong, S., Faurot, K. R., Broste, S. K., Frantz, R. P., Davis, J. M., Ringel, A., Suchindran, C. M., & Hibbeln, J. R. (2016). Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ, 353, i1246. https://doi.org/10.1136/bmj.i1246
Ravnskov, U., de Lorgeril, M., Kendrick, M., & Diamond, D. M. (2022). Importance of Coagulation Factors as Critical Components of Premature Cardiovascular Disease in Familial Hypercholesterolemia. Int J Mol Sci, 23(16), doi: 10.3390/ijms23169146. https://doi.org/10.3390/ijms23169146
Ray, K. K., Seshasai, S. R. K., Erqou, S., Sever, P., Jukema, J. W., Ford, I., & Sattar, N. (2010). Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med, 170(12), 1024-1031. https://doi.org/10.1001/archinternmed.2010.182
Redberg, R. F., & Katz, M. H. (2012). Healthy men should not take statins. JAMA, 307(14), 1491-2. https://doi.org/10.1001/jama.2012.423
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto AM Jr, Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Glynn, R. J. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 359(21), 2195-207. https://doi.org/10.1056/NEJMoa0807646
Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012). Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet, 380(9841), 565-71. https://doi.org/10.1016/S0140-6736(12)61190-8
Rizos, C. V., Elisaf, M. S., & Liberopoulos, E. N. (2011). Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J, 5, 76-84. https://doi.org/10.2174/1874192401105010076
Rodondi, N., den Elzen, W. P., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P., Asvold, B. O., Iervasi, G., Imaizumi, M., Collet, T. H., Bremner, A., Maisonneuve, P., Sgarbi, J. A., Khaw, K. T., Vanderpump, M. P., Newman, A. B., Cornuz, J., Franklyn, J. A., Westendorp, R. G., . . . Gussekloo, J. (2010). Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 304(12), 1365-74. https://doi.org/10.1001/jama.2010.1361
Ryan, T. E., Torres, M. J., Lin, C. T., Clark, A. H., Brophy, P. M., Smith, C. A., Smith, C. D., Morris, E. M., Thyfault, J. P., & Neufer, P. D. (2024). High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans. JCI Insight, 9(4), doi: 10.1172/jci.insight.174125. https://doi.org/10.1172/jci.insight.174125
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M., Wun, C. C., Davis, B. R., & Braunwald, E. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 335(14), 1001-9. https://doi.org/10.1056/NEJM199610033351401
Sağlam, H. S., Köse, O., Kumsar, S., Budak, S., & Adsan, O. (2012). Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer. ScientificWorldJournal, 2012, 696329. https://doi.org/10.1100/2012/696329
Salpeter, S. R., Walsh, J. M., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006). Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab, 8(5), 538-54. https://doi.org/10.1111/j.1463-1326.2005.00545.x
Sandwith, L., & Forget, P. (2021). Statins in Healthy Adults: A Meta-Analysis. Medicina (Kaunas), 57(6), doi: 10.3390/medicina57060585. https://doi.org/10.3390/medicina57060585
Savarese, G., Gotto, A. M., Jr., Paolillo, S., D'Amore, C., Losco, T., Musella, F., Scala, O., Marciano, C., Ruggiero, D., Marsico, F., De Luca, G., Trimarco, B., & Perrone-Filardi, P. (2013). Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol, 62(22), 2090-2099. https://doi.org/10.1016/j.jacc.2013.07.069
Schatz, I. J., Masaki, K., Yano, K., Chen, R., Rodriguez, B. L., & Curb, J. D. (2001). Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet, 358(9279), 351-5. https://doi.org/10.1016/S0140-6736(01)05553-2
Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., Stilgren, L., Eiken, P., Mosekilde, L., Køber, L., & Jensen, J. E. (2012). Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ, 345, e6409. https://doi.org/10.1136/bmj.e6409
Schmermund, A., Achenbach, S., Budde, T., Buziashvili, Y., Förster, A., Friedrich, G., Henein, M., Kerkhoff, G., Knollmann, F., Kukharchuk, V., Lahiri, A., Leischik, R., Moshage, W., Schartl, M., Siffert, W., Steinhagen-Thiessen, E., Sinitsyn, V., Vogt, A., Wiedeking, B., & Erbel, R. (2006). Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation, 113(3), 427-37. https://doi.org/10.1161/CIRCULATIONAHA.105.568147
Schooling, C. M., Au Yeung, S. L., Freeman, G., & Cowling, B. J. (2013). The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med, 11, 57. https://doi.org/10.1186/1741-7015-11-57
SEARCH Collaborative Group. (2008). SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med, 359(8), 789-99. https://doi.org/10.1056/NEJMoa0801936
SEARCH Collaborative Group. (2010). Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet, 376(9753), 1658-69. https://doi.org/10.1016/S0140-6736(10)60310-8
Shawish, M. I., Bagheri, B., Musini, V. M., Adams, S. P., & Wright, J. M. (2021). Effect of atorvastatin on testosterone levels. Cochrane Database Syst Rev, 1(1), CD013211. https://doi.org/10.1002/14651858.CD013211.pub2
Singh, B. M., Lamichhane, H. K., Srivatsa, S. S., Adhikari, P., Kshetri, B. J., Khatiwada, S., & Shrestha, D. B. (2020). Role of statins in the primary prevention of atherosclerotic cardiovascular disease and mortality in the population with mean cholesterol in the near-optimal to borderline high range: A systematic review and meta-analysis. Adv Prev Med, 2020, 6617905. https://doi.org/10.1155/2020/6617905
Slade, J. M., Abela, G. S., Rozman, M., McClowry, R. J., Hurley, D., Forbes, S. C., & Meyer, R. A. (2021). The impact of statin therapy and aerobic exercise training on skeletal muscle and whole-body aerobic capacity. Am Heart J Plus, 5, pii: 100028. doi: 10.1016/j.ahjo.2021.100028. https://doi.org/10.1016/j.ahjo.2021.100028
Sriprasert, I., Hodis, H. N., Bernick, B., Mirkin, S., & Mack, W. J. (2020). Effects of Estradiol Dose and Serum Estradiol Levels on Metabolic Measures in Early and Late Postmenopausal Women in the REPLENISH Trial. J Womens Health (Larchmt), 29(8), 1052-1058. https://doi.org/10.1089/jwh.2019.8238
Sriprasert, I., Kim, S. S., Mohammed, I. E., Kono, N., Karim, R., Allayee, H., Hodis, H. N., Mack, W. J., & Krauss, R. M. (2025). Effect of Hormone Therapy on Lipoprotein Subfractions in Early and Late Postmenopausal Women. J Clin Endocrinol Metab, 110(2), e301-e309. https://doi.org/10.1210/clinem/dgae171
Suneja, M., Fox, D. K., Fink, B. D., Herlein, J. A., Adams, C. M., & Sivitz, W. I. (2015). Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy. Transl Res, 166(2), 176-87. https://doi.org/10.1016/j.trsl.2015.01.007
Sung, K. C., Huh, J. H., Ryu, S., Lee, J. Y., Scorletti, E., Byrne, C. D., Kim, J. Y., Hyun, D. S., & Ko, S. B. (2019). Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statin Users. J Clin Med, 8(10), doi: 10.3390/jcm8101571. https://doi.org/10.3390/jcm8101571
Tavazzi, L., Maggioni, A. P., Marchioli, R., Barlera, S., Franzosi, M. G., Latini, R., Lucci, D., Nicolosi, G. L., Porcu, M., & Tognoni, G. (2008). Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet, 372(9645), 1231-9. https://doi.org/10.1016/S0140-6736(08)61240-4
Taylor, F., Ward, K., Moore, T. H., Burke, M., Davey Smith, G., Casas, J. P., & Ebrahim, S. (2011). Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev(1), CD004816. https://doi.org/10.1002/14651858.CD004816.pub4
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., & Ebrahim, S. (2013). Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2013(1), CD004816. https://doi.org/10.1002/14651858.CD004816.pub5
Taylor, B. A., Lorson, L., White, C. M., & Thompson, P. D. (2015). A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis, 238(2), 329-35. https://doi.org/10.1016/j.atherosclerosis.2014.12.016
Thavendiranathan, P., Bagai, A., Brookhart, M. A., & Choudhry, N. K. (2006). Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med, 166, 2307-2313.
Tonstad, S., Ose, L., Gørbitz, C., Djøseland, O., Bard, J. M., & Fruchart, J. C. (1995). Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. J Intern Med, 238(1), 39-47. https://doi.org/10.1111/j.1365-2796.1995.tb00897.x
Traish, A. M., Kang, H. P., Saad, F., & Guay, A. T. (2011). Dehydroepiandrosterone (DHEA)--a precursor steroid or an active hormone in human physiology. J Sex Med, 8(11), 2960-82; quiz 2983. https://doi.org/10.1111/j.1743-6109.2011.02523.x
Travison, T. G., Araujo, A. B., O'Donnell, A. B., Kupelian, V., & McKinlay, J. B. (2007). A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab, 92(1), 196-202. https://doi.org/10.1210/jc.2006-1375
Tsilingiris, D., Stratigou, T., Kounatidis, D., Vallianou, N. G., Karampela, I., & Dalamaga, M. (2025). Cardiometabolic risk profiles in subclinical hypothyroidism, and the potential impact of statin therapy: A cross-sectional and longitudinal study. Metabol Open, 27, 100394. https://doi.org/10.1016/j.metop.2025.100394
Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991). Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med, 325(17), 1196-204. https://doi.org/10.1056/NEJM199110243251702
Walsh, B. W., Li, H., & Sacks, F. M. (1994). Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res, 35(11), 2083-93.
Walsh, J. M., & Pignone, M. (2004). Drug treatment of hyperlipidemia in women. JAMA, 291(18), 2243-52. https://doi.org/10.1001/jama.291.18.2243
Wang, X., Li, J., Wang, T., Zhang, Z., Li, Q., Ma, D., Chen, Z., Ju, J., Xu, H., & Chen, K. (2022). Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials. Front Cardiovasc Med, 9, 929020. https://doi.org/10.3389/fcvm.2022.929020
Wannamethee, G., Shaper, A. G., Whincup, P. H., & Walker, M. (1995). Low serum total cholesterol concentrations and mortality in middle aged British men. BMJ, 311(7002), 409-13. https://doi.org/10.1136/bmj.311.7002.409
Waters, D. D. (2019). Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now. Can J Cardiol, 35(5), 590-597. https://doi.org/10.1016/j.cjca.2018.07.477
Weiss, E. P., Villareal, D. T., Fontana, L., Han, D. H., & Holloszy, J. O. (2011). Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY), 3(5), 533-42. https://doi.org/10.18632/aging.100327
Weverling-Rijnsburger, A. W., Blauw, G. J., Lagaay, A. M., Knook, D. L., Meinders, A. E., & Westendorp, R. G. (1997). Total cholesterol and risk of mortality in the oldest old. Lancet, 350(9085), 1119-23. https://doi.org/10.1016/s0140-6736(97)04430-9
WHI Writing Group. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-33. https://doi.org/10.1001/jama.288.3.321
Wittert, G., Bracken, K., Robledo, K. P., Grossmann, M., Yeap, B. B., Handelsman, D. J., Stuckey, B., Conway, A., Inder, W., McLachlan, R., Allan, C., Jesudason, D., Fui, M. N. T., Hague, W., Jenkins, A., Daniel, M., Gebski, V., & Keech, A. (2021). Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol, 9(1), 32-45. https://doi.org/10.1016/S2213-8587(20)30367-3
Wu, T. T., Chen, Y., Zhou, Y., Adi, D., Zheng, Y. Y., Liu, F., Ma, Y. T., & Xie, X. (2017). Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 6(5), doi: 10.1161/JAHA.116.004896. https://doi.org/10.1161/JAHA.116.004896
Wu, W., Xiao, Z., Liang, X., Zhao, Q., Luo, J., & Ding, D. (2022). Low and High-Density Lipoprotein Cholesterol and 10-Year Mortality in Community-Dwelling Older Adults: The Shanghai Aging Study. Front Med (Lausanne), 9, 783618. https://doi.org/10.3389/fmed.2022.783618
Xu, F., Yang, M., Hu, W., Yuan, S., Cai, X., Gou, W., Miao, Z., Li, B. Y., Yue, L., Xue, Z., Shuai, M., Shen, L., Fu, Y., Guo, T., Chen, Y. M., & Zheng, J. S. (2025). Cross-ethnic Molecular Signatures Underpin the Adverse Impact of Statin Use on Type 2 Diabetes. Genomics Proteomics Bioinformatics, 23(5), doi: 10.1093/gpbjnl/qzaf101. https://doi.org/10.1093/gpbjnl/qzaf101
Yebyo, H. G., Zappacosta, S., Aschmann, H. E., Haile, S. R., & Puhan, M. A. (2020). Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study. BMC Cardiovasc Disord, 20, 418. https://doi.org/10.1186/s12872-020-01697-6
Yi, S. W., Yi, J. J., & Ohrr, H. (2019). Total cholesterol and all-cause mortality by sex and age: a prospective cohort study among 12.8 million adults. Sci Rep, 9(1), 1596. https://doi.org/10.1038/s41598-018-38461-y
Yourman, L. C., Cenzer, I. S., Boscardin, W. J., Nguyen, B. T., Smith, A. K., Schonberg, M. A., Schoenborn, N. L., Widera, E. W., Orkaby, A., Rodriguez, A., & Lee, S. J. (2021). Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis. JAMA Intern Med, 181(2), 179-185. https://doi.org/10.1001/jamainternmed.2020.6084
Zhou, Z., Tonkin, A. M., Curtis, A. J., Murray, A., Zhu, C., Reid, C. M., Williamson, J. D., Ryan, J., McNeil, J. J., Beilin, L. J., Ernst, M. E., Stocks, N., Lacaze, P., Shah, R. C., Woods, R. L., Wolfe, R., Gall, S., Zoungas, S., Orchard, S. G., & Nelson, M. R. (2024). Low-Density-Lipoprotein Cholesterol and Mortality Outcomes Among Healthy Older Adults: A Post Hoc Analysis of ASPREE Trial. J Gerontol A Biol Sci Med Sci, 79(4), doi: 10.1093/gerona/glad268. https://doi.org/10.1093/gerona/glad268
Zoungas, S., Wolfe, R., Moran, C., Nicholls, S. J., Cloud, G. C., Reid, C. M., Τonkin, A. M., Beilin, L., Wierzbicki, A. S., Chong, T. T., Broder, J. C., Curtis, A. J., Flanagan, Z., Hopper, I., Ryan, J., Spark, S., McNeil, J. J., & Nelson, M. R. (2026). Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. N Engl J Med, 395(13), 1259-1272. https://doi.org/10.1056/NEJMoa2607314
